ABBOTINDIA Hits All-Time High!

(₹34,940) rallied 17% last week, touching a new all-time high of ₹37,000. On Friday, it gained 5.7%, marking its fourth consecutive positive close. A subsidiary of Abbott Laboratories, the company is a key player in India's pharmaceutical sector, known for high-quality products across therapeutic categories. Historically strong, ABBOTINDIA has delivered positive annual returns every year since 2010, except 2016. In 2025 YTD (till June 27), the stock has already surged 17.48%. Strong fundamentals—ROE of 32.48%, ROCE of 42.51%, and dividend yield of 2.53%—make it a compelling mid-cap with ₹74,391 Cr. market cap. Investors may consider keeping this resilient performer on their watchlist. Disclaimer: This post is intended solely for informational purposes and should not be construed as a recommendation to buy, sell, or hold any security. Investors are advised to consult their certified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. Please read all relevant offer documents and disclosures carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide assurance of returns to investors. The securities and charts quoted herein, if any, are purely illustrative and are not to be interpreted as recommendatory. Past performance is not indicative of future results.